Bispecific T-cells (BiTE), CAR T-cell therapies and antibody-drug conjugates (ADCs) have revolutionised the treatment of haematological malignancies. However, accessibility and unexplored clinical issues present challenges for patients and clinicians for optimal integration into treatment regimens. The lowest barrier to access is for ADCs, largely because the institutional set-up for administration would be minimal. However, for CAR T cells and BiTEs, it is different. There is a significant learning curve for many parts of an institution. There must be appropriate medical expertise, pharmacy expertise, nursing expertise and the administration has to be willing to support it. With CAR T cell therapy, an institution must go through the accreditation process and dedicate institutional resources in terms of location and space for appropriate cell processing facilities.